Solid Organ Transplantation Pharmacogenomics and Drug-Drug Interactions Quiz
21 Questions
1 Views

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What is pharmacogenomics?

  • The study of how drugs affect genetic variations.
  • The study of how drug interactions affect genetic variations.
  • The study of how genetic variations affect drug response and toxicity. (correct)
  • The study of how lifestyle factors affect drug response and toxicity.

    • Which enzymes contribute to the metabolism of tacrolimus, cyclosporine, and sirolimus and exhibit genetic polymorphisms?

  • CYP2C19, CYP2C8, and P-glycoprotein
  • CYP3A5, CYP3A4, and P-glycoprotein (correct)
  • CYP3A5, CYP3A4, and MDR1
  • CYP2D6, CYP2C9, and CYP1A2

    • What is the function of the MDR1 gene?

  • Encodes CYP3A4, which is an enzyme that contributes to drug metabolism.
  • Encodes P-glycoprotein, which is an ATP-driven efflux pump that can impact drug disposition. (correct)
  • Encodes CYP3A5, which is an enzyme that contributes to drug metabolism.
  • Encodes UGT1A9, which is an enzyme that metabolizes mycophenolic acid.

    • What is the activity of mycophenolic acid (MPA) derived from?

    <p>Its inhibition of inosine monophosphate dehydrogenase (IMPDH)</p> Signup and view all the answers

    What can cause variability in pharmacokinetics of immunosuppressants?

    <p>Patient factors, genetic polymorphisms, and drug-drug interactions</p> Signup and view all the answers

    What is the role of CYP3A5 in CYP3A-dependent drug clearance?

    <p>CYP3A5 may represent up to 50% of the total hepatic CYP3A content in people who are CYP3A5*1/<em>3 or CYP3A5</em>1/*1, and may contribute to inter-individual and inter-racial differences in CYP3A-dependent drug clearance.</p> Signup and view all the answers

    What can drug-drug interactions do to the blood concentrations of cyclosporine, tacrolimus, sirolimus, and everolimus?

    <p>Affect them</p> Signup and view all the answers

    What is the recommended approach for avoiding interactions between sirolimus and CNIs?

    <p>Separate administration times</p> Signup and view all the answers

    Which enzyme contributes to the metabolism of tacrolimus, cyclosporine, and sirolimus and exhibits genetic polymorphisms?

    <p>CYP3A5</p> Signup and view all the answers

    What is the impact of an SNP in intron 3 of the CYP3A5 gene?

    <p>It causes a splicing error and aberrantly spliced mRNA with a premature stop codon, resulting in significantly reduced enzyme expression.</p> Signup and view all the answers

    What is the activity of MPA derived from?

    <p>Its inhibition of IMPDH</p> Signup and view all the answers

    What is the potential benefit of prospective genotyping for CYP3A5?

    <p>To predict the risk of CYP3A5-induced nephrotoxicity</p> Signup and view all the answers

    Which substances can reduce blood levels of Cellcept® and Myfortic® significantly?

    <p>Antacids, cholestyramine, and calcium polycarbophil</p> Signup and view all the answers

    What is the major importance of xanthine oxidase in the metabolism of azathioprine metabolites?

    <p>It is of major importance in the metabolism of azathioprine metabolites</p> Signup and view all the answers

    Which drugs can induce hepatic metabolism of prednisone, decreasing its effectiveness?

    <p>Barbiturates, phenytoin, and rifampin</p> Signup and view all the answers

    What is the impact of co-administration of CNIs with NSAIDs and other renal-dysfunction-inducing drugs?

    <p>It causes additive nephrotoxicity</p> Signup and view all the answers

    Pharmacogenetics and pharmacogenomics have no impact on drug response and toxicity

    <p>False</p> Signup and view all the answers

    Variability in pharmacokinetics of immunosuppressants cannot be caused by genetic polymorphisms

    <p>False</p> Signup and view all the answers

    CYP3A5, CYP3A4, and P-glycoprotein are enzymes and transporters that contribute to the metabolism of tacrolimus, cyclosporine, and sirolimus and exhibit genetic polymorphisms

    <p>True</p> Signup and view all the answers

    Co-administration of cyclosporine and ketoconazole can lead to savings of nearly $5,000/year per transplant recipient

    <p>True</p> Signup and view all the answers

    What is the function of P-glycoprotein?

    <p>An ATP-driven efflux pump that can impact drug disposition</p> Signup and view all the answers

    Study Notes

    Solid Organ Transplantation Pharmacogenomics and Drug-Drug Interactions

    • Pharmacogenetics and pharmacogenomics are the study of how genetic variations affect drug response and toxicity.

    • Variability in pharmacokinetics of immunosuppressants can be caused by patient factors, genetic polymorphisms, and drug-drug interactions.

    • CYP3A5, CYP3A4, and P-glycoprotein are enzymes and transporters that contribute to the metabolism of tacrolimus, cyclosporine, and sirolimus and exhibit genetic polymorphisms.

    • The MDR1 gene encodes P-glycoprotein, which is an ATP-driven efflux pump that can impact drug disposition.

    • An SNP in intron 3 of the CYP3A5 gene causes a splicing error and aberrantly spliced mRNA with a premature stop codon, resulting in significantly reduced enzyme expression.

    • CYP3A5 may represent up to 50% of the total hepatic CYP3A content in people who are CYP3A5*1/3 or CYP3A51/*1, and may contribute to inter-individual and inter-racial differences in CYP3A-dependent drug clearance.

    • Mycophenolic acid (MPA) has several UGTs that metabolize it, and two SNPs in UGT1A9 have been associated with lower overall exposure to MPA.

    • The activity of MPA is derived from its inhibition of inosine monophosphate dehydrogenase (IMPDH), and reports suggest that IMPDH polymorphisms could play a part in the activity of MPA.

    • CNI-mediated nephrotoxicity may be due to intrarenal accumulation of the parent drug, but conversion of parent drug to metabolite can serve as a protective mechanism from damage to the kidney.

    • Prospective genotyping for CYP3A5 may be beneficial for initial dose selection of tacrolimus and sirolimus, and may help predict the risk of CNI-induced nephrotoxicity.

    • CYP3A5 genotyping might also be of some clinical value in predicting the risk of CNI-induced nephrotoxicity and in medication selection for patients with a higher risk for renal dysfunction.

    • Drug-drug interactions can affect the blood concentrations of cyclosporine, tacrolimus, sirolimus, and everolimus, and substances that inhibit CYP3A4/5 can increase drug concentrations, while drugs that induce CYP3A activity can decrease drug concentrations.Drug Interactions in Solid-Organ Transplantation

    • Sirolimus and CNIs require separate administration times to avoid interactions.

    • Sirolimus exacerbates CNI-induced renal dysfunction, while CNIs increase sirolimus-induced hyperlipidemia and myelosuppression.

    • Co-administration of CNIs with NSAIDs and other renal-dysfunction-inducing drugs can cause additive nephrotoxicity.

    • CNIs can elevate methotrexate levels and reduce clearance of drugs like prednisolone, digoxin, and statins.

    • Co-administration of cyclosporine and ketoconazole can significantly elevate blood levels of cyclosporine, requiring a decrease in dosage regimen.

    • The interaction between cyclosporine and ketoconazole can lead to savings of nearly $5,000/year per transplant recipient.

    • Antacids, cholestyramine, and calcium polycarbophil can reduce blood levels of Cellcept® and Myfortic® significantly.

    • Xanthine oxidase, blocked by allopurinol, is of major importance in the metabolism of azathioprine metabolites, and the combination of azathioprine with allopurinol should be avoided.

    • Adverse effects resulting from co-administration of azathioprine with other myelosuppressive agents or angiotensin-converting enzyme inhibitors include leukopenia, thrombocytopenia, and anemia as a result of myelosuppression.

    • Barbiturates, phenytoin, and rifampin induce hepatic metabolism of prednisone, decreasing its effectiveness.

    • Prednisone decreases the effectiveness of vaccines and toxoids.

    • For questions, contact [email protected].

    Solid Organ Transplantation Pharmacogenomics and Drug-Drug Interactions

    • Pharmacogenetics and pharmacogenomics are the study of how genetic variations affect drug response and toxicity.

    • Variability in pharmacokinetics of immunosuppressants can be caused by patient factors, genetic polymorphisms, and drug-drug interactions.

    • CYP3A5, CYP3A4, and P-glycoprotein are enzymes and transporters that contribute to the metabolism of tacrolimus, cyclosporine, and sirolimus and exhibit genetic polymorphisms.

    • The MDR1 gene encodes P-glycoprotein, which is an ATP-driven efflux pump that can impact drug disposition.

    • An SNP in intron 3 of the CYP3A5 gene causes a splicing error and aberrantly spliced mRNA with a premature stop codon, resulting in significantly reduced enzyme expression.

    • CYP3A5 may represent up to 50% of the total hepatic CYP3A content in people who are CYP3A5*1/3 or CYP3A51/*1, and may contribute to inter-individual and inter-racial differences in CYP3A-dependent drug clearance.

    • Mycophenolic acid (MPA) has several UGTs that metabolize it, and two SNPs in UGT1A9 have been associated with lower overall exposure to MPA.

    • The activity of MPA is derived from its inhibition of inosine monophosphate dehydrogenase (IMPDH), and reports suggest that IMPDH polymorphisms could play a part in the activity of MPA.

    • CNI-mediated nephrotoxicity may be due to intrarenal accumulation of the parent drug, but conversion of parent drug to metabolite can serve as a protective mechanism from damage to the kidney.

    • Prospective genotyping for CYP3A5 may be beneficial for initial dose selection of tacrolimus and sirolimus, and may help predict the risk of CNI-induced nephrotoxicity.

    • CYP3A5 genotyping might also be of some clinical value in predicting the risk of CNI-induced nephrotoxicity and in medication selection for patients with a higher risk for renal dysfunction.

    • Drug-drug interactions can affect the blood concentrations of cyclosporine, tacrolimus, sirolimus, and everolimus, and substances that inhibit CYP3A4/5 can increase drug concentrations, while drugs that induce CYP3A activity can decrease drug concentrations.Drug Interactions in Solid-Organ Transplantation

    • Sirolimus and CNIs require separate administration times to avoid interactions.

    • Sirolimus exacerbates CNI-induced renal dysfunction, while CNIs increase sirolimus-induced hyperlipidemia and myelosuppression.

    • Co-administration of CNIs with NSAIDs and other renal-dysfunction-inducing drugs can cause additive nephrotoxicity.

    • CNIs can elevate methotrexate levels and reduce clearance of drugs like prednisolone, digoxin, and statins.

    • Co-administration of cyclosporine and ketoconazole can significantly elevate blood levels of cyclosporine, requiring a decrease in dosage regimen.

    • The interaction between cyclosporine and ketoconazole can lead to savings of nearly $5,000/year per transplant recipient.

    • Antacids, cholestyramine, and calcium polycarbophil can reduce blood levels of Cellcept® and Myfortic® significantly.

    • Xanthine oxidase, blocked by allopurinol, is of major importance in the metabolism of azathioprine metabolites, and the combination of azathioprine with allopurinol should be avoided.

    • Adverse effects resulting from co-administration of azathioprine with other myelosuppressive agents or angiotensin-converting enzyme inhibitors include leukopenia, thrombocytopenia, and anemia as a result of myelosuppression.

    • Barbiturates, phenytoin, and rifampin induce hepatic metabolism of prednisone, decreasing its effectiveness.

    • Prednisone decreases the effectiveness of vaccines and toxoids.

    • For questions, contact [email protected].

    Solid Organ Transplantation Pharmacogenomics and Drug-Drug Interactions

    • Pharmacogenetics and pharmacogenomics are the study of how genetic variations affect drug response and toxicity.

    • Variability in pharmacokinetics of immunosuppressants can be caused by patient factors, genetic polymorphisms, and drug-drug interactions.

    • CYP3A5, CYP3A4, and P-glycoprotein are enzymes and transporters that contribute to the metabolism of tacrolimus, cyclosporine, and sirolimus and exhibit genetic polymorphisms.

    • The MDR1 gene encodes P-glycoprotein, which is an ATP-driven efflux pump that can impact drug disposition.

    • An SNP in intron 3 of the CYP3A5 gene causes a splicing error and aberrantly spliced mRNA with a premature stop codon, resulting in significantly reduced enzyme expression.

    • CYP3A5 may represent up to 50% of the total hepatic CYP3A content in people who are CYP3A5*1/3 or CYP3A51/*1, and may contribute to inter-individual and inter-racial differences in CYP3A-dependent drug clearance.

    • Mycophenolic acid (MPA) has several UGTs that metabolize it, and two SNPs in UGT1A9 have been associated with lower overall exposure to MPA.

    • The activity of MPA is derived from its inhibition of inosine monophosphate dehydrogenase (IMPDH), and reports suggest that IMPDH polymorphisms could play a part in the activity of MPA.

    • CNI-mediated nephrotoxicity may be due to intrarenal accumulation of the parent drug, but conversion of parent drug to metabolite can serve as a protective mechanism from damage to the kidney.

    • Prospective genotyping for CYP3A5 may be beneficial for initial dose selection of tacrolimus and sirolimus, and may help predict the risk of CNI-induced nephrotoxicity.

    • CYP3A5 genotyping might also be of some clinical value in predicting the risk of CNI-induced nephrotoxicity and in medication selection for patients with a higher risk for renal dysfunction.

    • Drug-drug interactions can affect the blood concentrations of cyclosporine, tacrolimus, sirolimus, and everolimus, and substances that inhibit CYP3A4/5 can increase drug concentrations, while drugs that induce CYP3A activity can decrease drug concentrations.Drug Interactions in Solid-Organ Transplantation

    • Sirolimus and CNIs require separate administration times to avoid interactions.

    • Sirolimus exacerbates CNI-induced renal dysfunction, while CNIs increase sirolimus-induced hyperlipidemia and myelosuppression.

    • Co-administration of CNIs with NSAIDs and other renal-dysfunction-inducing drugs can cause additive nephrotoxicity.

    • CNIs can elevate methotrexate levels and reduce clearance of drugs like prednisolone, digoxin, and statins.

    • Co-administration of cyclosporine and ketoconazole can significantly elevate blood levels of cyclosporine, requiring a decrease in dosage regimen.

    • The interaction between cyclosporine and ketoconazole can lead to savings of nearly $5,000/year per transplant recipient.

    • Antacids, cholestyramine, and calcium polycarbophil can reduce blood levels of Cellcept® and Myfortic® significantly.

    • Xanthine oxidase, blocked by allopurinol, is of major importance in the metabolism of azathioprine metabolites, and the combination of azathioprine with allopurinol should be avoided.

    • Adverse effects resulting from co-administration of azathioprine with other myelosuppressive agents or angiotensin-converting enzyme inhibitors include leukopenia, thrombocytopenia, and anemia as a result of myelosuppression.

    • Barbiturates, phenytoin, and rifampin induce hepatic metabolism of prednisone, decreasing its effectiveness.

    • Prednisone decreases the effectiveness of vaccines and toxoids.

    • For questions, contact [email protected].

    Solid Organ Transplantation Pharmacogenomics and Drug-Drug Interactions

    • Pharmacogenetics and pharmacogenomics are the study of how genetic variations affect drug response and toxicity.

    • Variability in pharmacokinetics of immunosuppressants can be caused by patient factors, genetic polymorphisms, and drug-drug interactions.

    • CYP3A5, CYP3A4, and P-glycoprotein are enzymes and transporters that contribute to the metabolism of tacrolimus, cyclosporine, and sirolimus and exhibit genetic polymorphisms.

    • The MDR1 gene encodes P-glycoprotein, which is an ATP-driven efflux pump that can impact drug disposition.

    • An SNP in intron 3 of the CYP3A5 gene causes a splicing error and aberrantly spliced mRNA with a premature stop codon, resulting in significantly reduced enzyme expression.

    • CYP3A5 may represent up to 50% of the total hepatic CYP3A content in people who are CYP3A5*1/3 or CYP3A51/*1, and may contribute to inter-individual and inter-racial differences in CYP3A-dependent drug clearance.

    • Mycophenolic acid (MPA) has several UGTs that metabolize it, and two SNPs in UGT1A9 have been associated with lower overall exposure to MPA.

    • The activity of MPA is derived from its inhibition of inosine monophosphate dehydrogenase (IMPDH), and reports suggest that IMPDH polymorphisms could play a part in the activity of MPA.

    • CNI-mediated nephrotoxicity may be due to intrarenal accumulation of the parent drug, but conversion of parent drug to metabolite can serve as a protective mechanism from damage to the kidney.

    • Prospective genotyping for CYP3A5 may be beneficial for initial dose selection of tacrolimus and sirolimus, and may help predict the risk of CNI-induced nephrotoxicity.

    • CYP3A5 genotyping might also be of some clinical value in predicting the risk of CNI-induced nephrotoxicity and in medication selection for patients with a higher risk for renal dysfunction.

    • Drug-drug interactions can affect the blood concentrations of cyclosporine, tacrolimus, sirolimus, and everolimus, and substances that inhibit CYP3A4/5 can increase drug concentrations, while drugs that induce CYP3A activity can decrease drug concentrations.Drug Interactions in Solid-Organ Transplantation

    • Sirolimus and CNIs require separate administration times to avoid interactions.

    • Sirolimus exacerbates CNI-induced renal dysfunction, while CNIs increase sirolimus-induced hyperlipidemia and myelosuppression.

    • Co-administration of CNIs with NSAIDs and other renal-dysfunction-inducing drugs can cause additive nephrotoxicity.

    • CNIs can elevate methotrexate levels and reduce clearance of drugs like prednisolone, digoxin, and statins.

    • Co-administration of cyclosporine and ketoconazole can significantly elevate blood levels of cyclosporine, requiring a decrease in dosage regimen.

    • The interaction between cyclosporine and ketoconazole can lead to savings of nearly $5,000/year per transplant recipient.

    • Antacids, cholestyramine, and calcium polycarbophil can reduce blood levels of Cellcept® and Myfortic® significantly.

    • Xanthine oxidase, blocked by allopurinol, is of major importance in the metabolism of azathioprine metabolites, and the combination of azathioprine with allopurinol should be avoided.

    • Adverse effects resulting from co-administration of azathioprine with other myelosuppressive agents or angiotensin-converting enzyme inhibitors include leukopenia, thrombocytopenia, and anemia as a result of myelosuppression.

    • Barbiturates, phenytoin, and rifampin induce hepatic metabolism of prednisone, decreasing its effectiveness.

    • Prednisone decreases the effectiveness of vaccines and toxoids.

    • For questions, contact [email protected].

    Studying That Suits You

    Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

    Quiz Team

    Related Documents

    SOT3_DDI and PGx_53.pptx

    Description

    Test your knowledge on Solid Organ Transplantation Pharmacogenomics and Drug-Drug Interactions with this quiz! Learn about how genetic variations can affect drug response and toxicity, the enzymes and transporters that contribute to the metabolism of immunosuppressants, and how drug-drug interactions can impact blood levels of certain drugs. This quiz covers important information for healthcare professionals involved in solid organ transplantation.

    More Like This

    Solid Organ Transplantation
    29 questions

    Solid Organ Transplantation

    DignifiedEnlightenment avatar
    DignifiedEnlightenment
    Test Your Knowledge on Pharmacotherapy in Solid Organ Transplantation
    20 questions

    Test Your Knowledge on Pharmacotherapy in Solid Organ Transplantation

    DignifiedEnlightenment avatar
    DignifiedEnlightenment
    Solid Organ Transplant Infections Quiz
    24 questions

    Solid Organ Transplant Infections Quiz

    DignifiedEnlightenment avatar
    DignifiedEnlightenment
    Solid Organ Transplantation Basics
    44 questions

    Solid Organ Transplantation Basics

    medgen avatar
    medgen
    Use Quizgecko on...
    Browser
    Open
    Browser
    Browser